发作性睡病I型(NT1)是一种罕见的慢性中枢神经系统疾病，由于患者的食欲素神经元大量缺失，导致大脑和脑脊液中食欲素神经肽水平低下。NT1患者常 常有日间过度思睡(EDS)、猝倒(即肌肉张力突然丧失)、夜间睡眠紊乱、入睡前和清醒前幻觉以及睡眠瘫痪等临床症状。 奥博雷通片是一种在研选择性OX2R激动剂，可选择性地刺激OX2R以恢复其信号传导，并改善因食欲素缺乏而导致的NT1。2025年7月，武田宣布奥博雷 通片的两项针对NT1的3期研究达到所有主要和次要终点。 中国国家药监局药品审评中心官网近日公示显示，武田(TAK.US)申报的1类新药奥博雷通片(oveporexton，TAK-861片)的上市申请拟纳入优先审评，适用 于治疗16岁及以上1型发作性睡病(NT1)患者。公开资料显示，这是武田研发的一款口服选择性食欲素2型受体(OX2R)激动剂。该产品针对NT1适应症的两 项3期关键性研究已经达到所有主要和次要终点。 | 优先审评公示详细信息 | | | | | --- | --- | --- | --- | | 광택음 | JXHS2600015 奥博雷通片 (TAK-861片) | 药品名称 | | | 机号 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.52% on January 19, 2025, underperforming the CSI 300 index by 0.57 percentage points, ranking 28th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.39%) and blood products (+0.11%), while sectors such as medical R&D outsourcing (-1.77%) and vaccines (-1.10%) lagged behind [4]. - Takeda's new drug Oveporexton has received acceptance for its market application in China, targeting narcolepsy type 1 (NT1) and showing promising results in clinical trials [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

Core Viewpoint - Takeda's investigational oral selective orexin 2 receptor (OX2R) agonist, oveporexton (development code: TAK-861), is positioned for regulatory approval in the second half of 2026, targeting narcolepsy type 1 (NT1) [2] Group 1: Product Development - Ovaporexton has been included in the breakthrough therapy designation by the CDE for the treatment of NT1 [2] - Two pivotal Phase 3 studies for oveporexton have met all primary and secondary endpoints [2] - Takeda has a diversified pipeline of orexin products, with orexin being a key regulator of sleep-wake patterns and involved in attention, mood, metabolism, and respiration [2] Group 2: Regulatory and Market Position - The product is expected to receive regulatory approval from authorities in the United States (FDA) and China (CDE) as a breakthrough therapy for NT1 [2]